NCT05968326 2026-03-12
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
Clinical Trials
97 trialsNCT06901531 2026-03-11
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT06902545 2026-03-11
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
Astellas Pharma Inc
Recruiting
NCT07023315 2026-02-11
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Akeso
Phase 3 Recruiting
NCT00349830 2026-02-10
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Stanford University
Recruiting
NCT07385703 2026-02-04
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT06693128 2026-01-28
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
Ruijin Hospital
Phase 2 Active not recruiting
NCT04208347 2026-01-23
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
Ruijin Hospital
Phase 2/3 Active not recruiting
NCT06967987 2026-01-21
BEMAFLOT
Institut Cancerologie de l'Ouest
Phase 2 Withdrawn
NCT05273554 2026-01-12
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04361708 2025-10-01
I-FLOAT
University of Chicago
Phase 1 Recruiting
NCT05116072 2025-09-25
TPIAT-01
University Hospital, Lille
Phase 1/2 Recruiting
NCT06048081 2025-09-10
Early Access Program for Zolbetuximab
Astellas Pharma Inc
Available
NCT07018570 2025-08-26
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Recruiting
NCT05892926 2025-07-20
HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia
AstraZeneca
Completed
NCT04879368 2025-07-17
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
Phase 3 Active not recruiting
NCT05065736 2025-07-11
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT06942767 2025-04-27
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT02818829 2025-03-21
BACAP
University Hospital, Toulouse
Active not recruiting
NCT04627246 2025-02-25
Personalized Vaccine with SOC Chemo Followed by Nivo in Pancreatic Cancer
Centre Hospitalier Universitaire Vaudois
Phase 1 Active not recruiting
NCT06128343 2025-02-03
BACAP-2
University Hospital, Toulouse
Recruiting
NCT01010945 2024-11-21
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
Astellas Pharma Inc
Phase 1 Completed
NCT04086758 2024-11-20
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Inc
Phase 1 Completed
NCT02292641 2024-10-17
Beyond TME Origins
Imperial College London
Phase NA Recruiting
NCT06599749 2024-09-19
Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Advanced and Metastatic High-Grade Adenocarcinoma of Ovarian, Tubal or Peritoneal Origin (TUPRO-Gyn)
University Hospital, Basel, Switzerland
Completed
NCT05101356 2024-05-21
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
University of California, Davis
Phase 1/2 Recruiting
NCT06405035 2024-05-08
MIMETIC
European Institute of Oncology
Recruiting
NCT04309578 2024-02-28
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Asan Medical Center
Phase 2 Unknown
NCT03997448 2024-02-20
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT06238752 2024-02-02
RENMIN-213
Renmin Hospital of Wuhan University
Phase 2 Completed
NCT03722108 2023-10-16
REGIRI
UNICANCER
Phase 1/2 Terminated
NCT05968196 2023-08-01
HCC and FTC
The Catholic University of Korea
Completed
NCT05964543 2023-07-28
The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors
QureBio Ltd.
Phase 1/2 Unknown
NCT01220752 2022-09-01
IMRT-HIT-SNT
Heidelberg University
Phase 2 Completed
NCT04483726 2022-08-22
DIPLOMA
University Hospital, Montpellier
Phase NA Unknown
NCT03000179 2022-04-14
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT02773524 2022-01-13
INTEGRATEIIa
Australasian Gastro-Intestinal Trials Group
Phase 3 Unknown
NCT01660711 2021-11-08
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Endeavor Health
Phase 2 Completed
NCT02426879 2021-09-30
Node
UMC Utrecht
Phase NA Completed
NCT03536182 2021-05-26
CIPHER
University of Texas Southwestern Medical Center
Phase 3 Withdrawn
NCT02564367 2021-04-29
S-1 adjuvant
AIO-Studien-gGmbH
Phase 1/2 Completed
NCT02987829 2021-04-23
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT02213289 2021-04-08
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
University of Chicago
Phase 2 Completed
NCT03578939 2021-03-18
LAPC-NGS-A/001
Istituto Clinico Humanitas
Completed
NCT01206296 2021-03-09
Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
Medstar Health Research Institute
Phase 2 Terminated
NCT02795650 2021-02-26
AVATAR
Hospital Universitario de Fuenlabrada
Phase 2 Unknown
NCT00247936 2021-01-26
Combined Thoracoscopic and Laparoscopic Esophagectomy vs. Hand-assisted Transhiatal Esophagectomy: A Prospective Trial.
University of California, Irvine
Phase NA Withdrawn
NCT01579994 2020-12-30
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01295086 2020-11-02
Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer
Odense University Hospital
Phase NA Completed
NCT04315155 2020-10-28
BENEFIT
University of Utah
Phase 1 Withdrawn